United States

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

24 Mar 2017
Change (% chg)

$0.93 (+0.80%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ICPT.OQ


Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic... (more)


Beta: -1.92
Market Cap(Mil.): $2,898.58
Shares Outstanding(Mil.): 24.83
Dividend: --
Yield (%): --


  ICPT.OQ Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -16.74 -- --
ROI: -65.06 -2.56 13.01
ROE: -90.03 5.14 14.16

BRIEF-Intercept Pharmaceuticals reports Q4 sales $13.8 mln

* Intercept pharmaceuticals reports full year 2016 financial results and provides business update

Feb 23 2017

BRIEF-Intercept Pharmaceuticals to update on trial of liver fibrosis treatment

* Intercept to provide update on phase 3 regenerate trial of obeticholic acid for the treatment of nash patients with liver fibrosis Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Feb 10 2017

Intercept Pharma's liver drug wins conditional EU approval

Intercept Pharmaceuticals Inc said its liver drug received conditional approval from the European Commission to treat patients with primary biliary cholangitis (PBC), a rare liver condition.

Dec 14 2016

BRIEF-Intercept Pharmaceuticals Q3 sales $4.7 million

* Intercept pharmaceuticals inc- eu marketing approval decision for ocaliva anticipated by year end 2016

Nov 03 2016

BRIEF-Intercept Pharmaceuticals receives positive CHMP opinion for ocaliva for treatment of primary biliary cholangitis in the EU

* Intercept pharmaceuticals receives positive chmp opinion for ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis in the European Union Source text for Eikon: Further company coverage:

Oct 14 2016

More From Around the Web


Earnings vs. Estimates